Company / Operating Cash Flow
MADRIGAL PHARMACEUTICALS, INC. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$189.6M
FY2025
5-year range
-$455.6M / -$183.9M
FY2021-FY2025
Trend
+58.4%
vs FY2024
Sector context
#167 of 216
Health Care
What the data says
MADRIGAL PHARMACEUTICALS, INC.'s operating cash flow of -$190M is lower than 77% of companies in the Health Care sector (FY2025). Operating Cash Flow returned to growth in FY2025 after 8 years of decline, reaching -$190M.
Based on SEC 10-K filings.
-$190M in FY2025.
Improved from -$324M to -$190M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 216This company -$189.6M Sector average $658.7M
▼
-128.8% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 58.4% year-over-year.
- Ranks #167 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2016.
- Lowest operating cash flow in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$189.6M | +58.4% |
| FY2024 | -$455.6M | -40.5% |
| FY2023 | -$324.2M | -44.2% |
| FY2022 | -$224.9M | -22.3% |
| FY2021 | -$183.9M | -16.7% |
| FY2020 | -$157.6M | -278.5% |
| FY2019 | -$41.6M | -63.2% |
| FY2018 | -$25.5M | -14.3% |
| FY2017 | -$22.3M | -26.7% |
| FY2016 | -$17.6M | +77.7% |
As of FY2025 · SEC 10-K · Updated Mar 29, 2026